Research
Print page Print page
Switch language
Hvidovre Hospital - a part of Copenhagen University Hospital
Published

Statins in High-Risk Chronic Obstructive Pulmonary Disease Outpatients: No Impact on Time to First Exacerbation and All-Cause Mortality - The STATUETTE Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Withdrawal of Inhaled Corticosteroids in Patients with COPD - A Prospective Observational Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. High suPAR and Low Blood Eosinophil Count are Risk Factors for Hospital Readmission and Mortality in Patients with COPD

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Self-reported vs. objectively assessed adherence to inhaled corticosteroids in asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Plasma marker for systemic inflammation is increased in Mexican Tarahumara following ultra-distance running

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: Statins have, due to their anti-inflammatory properties, been suggested to potentially improve chronic obstructive pulmonary disease (COPD) outcomes. We aimed to investigate the effect of statins on time to first exacerbation and all-cause mortality in high-risk COPD outpatients.

Methods: All outpatients with COPD seen at the Department of Respiratory Medicine, Copenhagen University Hospital Amager and Hvidovre, Denmark in 2016 were identified and followed for 3.5 years in this retrospective, registry-based cohort study of time to first acute exacerbation of COPD (AECOPD) or death. AECOPD was defined as a rescue course of oral corticosteroid and/or hospital admission. The association was estimated using time-varying crude and multivariable Cox proportional hazard regression.

Results: The cohort comprised 950 COPD outpatients, mean (SD) age 71 (11) years, and FEV1 44% predicted (IQR 33%; 57%). The annual exacerbation rate was 0.88 (1.68) and 211 patients (22%) had a history of hospital admission for AECOPD in the 12 months prior to index date. Three hundred and ninety-three patients (41.4%) were defined as statin users, with 131 (33.3%) having filled the first prescription for statin after index date. Statin use was not associated with reduced risk of AECOPD. When stratifying for moderate and severe exacerbations in a sub-analysis in the same model, statin use did not have an increased HR for exacerbation of either severity (HR = 1.02 (95% CI 0.85to 1.24; p = 0.811) and HR = 1.07 (95% CI 0.89 to 1.29; p = 0.492) respectively). Statin use was not associated with all-cause mortality (HR 1.05 (95% CI, 0.75 to 1.47, p = 0.777)).

Conclusion: We did not find any association between statin use and risk of AECOPD or all-cause mortality. The result adds to the evidence that an aggressive approach with statin treatment upfront is not beneficial in COPD, unless prescribed according to current guidelines for cardiovascular diseases.

Original languageEnglish
JournalInternational Journal of Chronic Obstructive Pulmonary Disease
Volume16
Pages (from-to)579-589
Number of pages11
ISSN1178-2005
DOIs
Publication statusPublished - 5 Mar 2021

Bibliographical note

Publisher Copyright:
© 2021 Damkjær et al.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

    Research areas

  • Cardiovascular disease, Chronic obstructive pulmonary disease, Exacerbations, Mortality, Statins

ID: 64229833